Summit Trail Advisors LLC Has $1.75 Million Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Summit Trail Advisors LLC increased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 22.1% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 20,884 shares of the biopharmaceutical company’s stock after purchasing an additional 3,779 shares during the period. Summit Trail Advisors LLC’s holdings in Gilead Sciences were worth $1,751,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the business. Waverly Advisors LLC grew its position in Gilead Sciences by 7.8% in the 1st quarter. Waverly Advisors LLC now owns 26,455 shares of the biopharmaceutical company’s stock worth $1,938,000 after purchasing an additional 1,910 shares in the last quarter. Bayesian Capital Management LP bought a new stake in shares of Gilead Sciences during the 1st quarter valued at about $1,187,000. Kennedy Capital Management LLC bought a new stake in Gilead Sciences during the first quarter worth about $2,946,000. Jacobs Levy Equity Management Inc. boosted its position in Gilead Sciences by 306.2% during the first quarter. Jacobs Levy Equity Management Inc. now owns 517,770 shares of the biopharmaceutical company’s stock valued at $37,927,000 after buying an additional 390,301 shares during the period. Finally, Elkhorn Partners Limited Partnership increased its stake in shares of Gilead Sciences by 171.4% in the first quarter. Elkhorn Partners Limited Partnership now owns 950 shares of the biopharmaceutical company’s stock worth $70,000 after buying an additional 600 shares during the period. 83.67% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total value of $167,660.00. Following the sale, the insider now owns 100,189 shares of the company’s stock, valued at approximately $8,398,843.87. The trade was a 1.96 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Johanna Mercier sold 29,357 shares of Gilead Sciences stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $83.78, for a total value of $2,459,529.46. Following the completion of the sale, the insider now directly owns 78,127 shares in the company, valued at $6,545,480.06. This represents a 27.31 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 56,947 shares of company stock worth $4,968,674 over the last ninety days. Corporate insiders own 0.29% of the company’s stock.

Gilead Sciences Stock Up 0.5 %

Shares of NASDAQ GILD opened at $90.19 on Monday. The stock has a market cap of $112.40 billion, a P/E ratio of 1,002.11, a PEG ratio of 2.80 and a beta of 0.17. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $98.90. The business’s fifty day simple moving average is $87.43 and its 200-day simple moving average is $76.95.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The business had revenue of $7.55 billion for the quarter, compared to analysts’ expectations of $7.01 billion. During the same period last year, the firm earned $2.29 earnings per share. The company’s revenue for the quarter was up 7.0% compared to the same quarter last year. As a group, equities analysts predict that Gilead Sciences, Inc. will post 4.37 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 30th. Shareholders of record on Friday, December 13th will be paid a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a yield of 3.42%. The ex-dividend date of this dividend is Friday, December 13th. Gilead Sciences’s dividend payout ratio is presently 3,422.22%.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on GILD. Wells Fargo & Company boosted their price target on shares of Gilead Sciences from $100.00 to $105.00 and gave the company an “overweight” rating in a research report on Thursday, November 7th. Evercore ISI upgraded Gilead Sciences to a “strong-buy” rating in a report on Friday, August 9th. Leerink Partnrs upgraded Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 21st. Wolfe Research assumed coverage on shares of Gilead Sciences in a research note on Friday, November 15th. They issued an “outperform” rating and a $110.00 price target on the stock. Finally, Truist Financial boosted their target price on Gilead Sciences from $83.00 to $97.00 and gave the stock a “hold” rating in a research report on Friday, November 8th. Twelve investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and four have given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $95.41.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.